Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Good catch. I noticed that too. Since I am just catching up on the volume of posts, I do not yet know whether this has been further discussed (= lack of additional secondary endpoints on clinical trials site)?
your chart does not look right
you wrote:
you wrote:
you wrote:
interesting thoughts re pspd
you wrote:
you wrote:
you wrote:
you wrote:
you wrote:
you wrote:
you wrote:
you wrote:
you wrote:
you wrote:
Looks promising for combination treatments. Recent Advances in Experimental Dendritic Cell Vaccines for Cancer
you wrote:
you wrote:
you wrote:
you wrote:
you wrote:
Although: before you write off Merlot altogether, you might want to give this one from Sonoma a try ....https://www.vivino.com/US/en/roth-merlot/w/1143021 ... 2016 Roth Merlot ... the 60% discount ain't bad either.
Current Immunotherapeutic Strategies for the Treatment of Glioblastoma
Mark Dapash, Brandyn Castro, David Hou and Catalina Lee-Chang
Cancers 2021,13,4548.
https://doi.org/ 10.3390/cancers13184548
Received: 16 July 2021 Accepted: 24 August 2021 Published: 10 September 2021
includes:
April podcast is now on website. https://pctl.com/wp-content/uploads/2022/04/PCT-April-Podcast-Update-2.mp3
I agree, interesting presentations today at the University of Miami by Dr. Liau.
Slide : Statistical analysis plan (SAP) for RCT with cross-over arm.
Linda Liau:
Quote:
"Before the trial was unblinded this was the statistical analysis plan that was submitted to the FDA."
this one?
Slide 23 at 3'58?
Statistical analysis plan (SAP) for RCT with cross-over arm.